EDG-7500 for Hypertrophic Cardiomyopathy
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with obstructive or nonobstructive hypertrophic cardiomyopathy (nHCM).
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, it does exclude participants who have used cardiac myosin inhibitors before, so you may need to discuss your current medications with the trial team.
How does the drug EDG-7500 differ from other treatments for hypertrophic cardiomyopathy?
EDG-7500 is unique because it may target the specific pathophysiology of hypertrophic cardiomyopathy, potentially offering a more precise treatment compared to traditional options like beta-blockers or septal reduction therapies. This approach could improve symptoms and functional capacity by addressing the underlying disease mechanisms.12345
Who Is on the Research Team?
Medical Director
Principal Investigator
Edgewise Therapeutics, Inc.
Are You a Good Fit for This Trial?
This trial is for adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle becomes abnormally thick. Participants should not have other serious medical conditions and must be able to follow the study procedures.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment Part A
Participants receive a single dose of EDG-7500
Treatment Part B
Participants receive EDG-7500 once daily for up to 28 days
Treatment Part C
Participants receive EDG-7500 once daily for up to 28 days
Treatment Part D
Participants receive EDG-7500 daily for up to 48 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- EDG-7500
Find a Clinic Near You
Who Is Running the Clinical Trial?
Edgewise Therapeutics, Inc.
Lead Sponsor